Exelixis Analyst Ratings

BenzingaMay 14 10:24 ET · Ratings

Exelixis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance With Its Midpoint Above Estimates. The Company, Acting as a Collaboration Partner of Invenra, Initiated the...

BenzingaMay 14 07:28 ET

BEIGENE's Q1 loss narrowed to 94.503 million yuan, with Baiyueze and Baizean sales revenue increasing.

In the first quarter of 2025, BEIGENE achieved revenue of 8.048 billion yuan, a year-on-year increase of 50.2%; the net income attributable to the parent was a loss of 94.503 million yuan, compared to a loss of 1.908 billion yuan in the same period last year; In recent years, with policy support, China's Innovative Drugs Industry has entered a period of rapid development. In 2024, the industry will usher in a new round of policy dividends, and the research and development results of domestic Innovative Drugs will experience explosive growth.

cls.cnMay 13 21:40 ET

Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors

BenzingaMay 13 18:09 ET

Earnings Preview: BeiGene

BenzingaMay 13 15:03 ET

Earnings Scheduled For May 13, 2025

BenzingaMay 13 04:32 ET